Received Apr 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | LM99N | — |
Maladministration of a pediatric dose on an adult patient; Wrong vaccination schedule (administration of a pediatric dose on an adult patient); This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a 71-year-old female patient who received HAV (Havrix 720) (batch number LM99N, expiry date 04-MAR-2026) for prophylaxis. On 08-OCT-2025, the patient received the 1st dose of Havrix 720. On 08-OCT-2025, an unknown time after receiving Havrix 720, the patient experienced adult use of a child product (Verbatim: Maladministration of a pediatric dose on an adult patient) and underdose (Verbatim: Wrong vaccination schedule (administration of a pediatric dose on an adult patient)). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date 14-APR-2026 The registered pharmacist reported maladministration of pediatric dose of the HAVRIX vaccine on adult patient, they want guidance on that matter. This was the first dose of the HAVRIX vaccine. No further information was obtained in this call. The reporter consented to follow up.